Boston Scientific Corporation $BSX is Banque Transatlantique SA’s 10th Largest Position

Banque Transatlantique SA grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 13.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,211,331 shares of the medical equipment provider’s stock after buying an additional 139,431 shares during the period. Boston Scientific accounts for 2.8% of Banque Transatlantique SA’s portfolio, making the stock its 10th largest position. Banque Transatlantique SA’s holdings in Boston Scientific were worth $115,459,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC raised its stake in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the second quarter valued at approximately $26,000. Main Street Financial Solutions LLC grew its stake in Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after purchasing an additional 1,971 shares in the last quarter. Ieq Capital LLC increased its holdings in Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after purchasing an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC increased its holdings in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after purchasing an additional 2,556 shares during the period. 89.07% of the stock is owned by institutional investors.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig purchased 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have acquired 9,800 shares of company stock worth $554,012. Insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $45.30 on Friday. The company has a 50 day moving average of $55.05 and a two-hundred day moving average of $73.22. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a twelve month low of $44.44 and a twelve month high of $109.50. The company has a market cap of $67.33 billion, a price-to-earnings ratio of 18.95, a price-to-earnings-growth ratio of 0.86 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the previous year, the business earned $0.75 EPS. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has initiated a share buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

Several brokerages have weighed in on BSX. Leerink Partners lowered their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a report on Thursday, May 28th. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research note on Thursday, May 28th. Barclays decreased their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Weiss Ratings lowered shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $88.00 target price (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $85.08.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.